The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
Current state of Alzheimer's fluid biomarkers
JL Molinuevo, S Ayton, R Batrla, MM Bednar… - Acta …, 2018 - Springer
Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …
heterogeneous pathophysiology. The number of people living with AD is predicted to …
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort …
T West, KM Kirmess, MR Meyer, MS Holubasch… - Molecular …, 2021 - Springer
Background The development of blood-based biomarker tests that are accurate and robust
for Alzheimer's disease (AD) pathology have the potential to aid clinical diagnosis and …
for Alzheimer's disease (AD) pathology have the potential to aid clinical diagnosis and …
The amyloid-β oligomer hypothesis: beginning of the third decade
The amyloid-β oligomer (AβO) hypothesis was introduced in 1998. It proposed that the brain
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …
damage leading to Alzheimer's disease (AD) was instigated by soluble, ligand-like AβOs …
Plasma lipidome is dysregulated in Alzheimer's disease and is associated with disease risk genes
Lipidomics research could provide insights of pathobiological mechanisms in Alzheimer's
disease. This study explores a battery of plasma lipids that can differentiate Alzheimer's …
disease. This study explores a battery of plasma lipids that can differentiate Alzheimer's …
Blood-based biomarkers for Alzheimer's disease diagnosis and progression: an overview
A Varesi, A Carrara, VG Pires, V Floris, E Pierella… - Cells, 2022 - mdpi.com
Alzheimer's Disease (AD) is a progressive neurodegenerative disease characterized by
amyloid-β (Aβ) plaque deposition and neurofibrillary tangle accumulation in the brain …
amyloid-β (Aβ) plaque deposition and neurofibrillary tangle accumulation in the brain …
Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances
Discovery and development of clinically useful biomarkers for Alzheimer's disease (AD) and
related dementias have been the focus of recent research efforts. While cerebrospinal fluid …
related dementias have been the focus of recent research efforts. While cerebrospinal fluid …
Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases
K Kulenkampff, AM Wolf Perez, P Sormanni… - Nature Reviews …, 2021 - nature.com
Protein misfolding and aggregation are characteristic of a wide range of neurodegenerative
disorders, including Alzheimer and Parkinson diseases. A hallmark of these diseases is the …
disorders, including Alzheimer and Parkinson diseases. A hallmark of these diseases is the …
Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder and affects more
than 10% of the population aged over 65 worldwide. Despite considerable global efforts, AD …
than 10% of the population aged over 65 worldwide. Despite considerable global efforts, AD …
Potential fluid biomarkers for the diagnosis of mild cognitive impairment
Mild cognitive impairment (MCI) is characterized by a level of cognitive impairment that is
lower than normal for a person's age, but a higher function than that that observed in a …
lower than normal for a person's age, but a higher function than that that observed in a …